Clemastine: Follow-Up Imaging Study Shows Some Evidence of Myelin Repair
June 29, 2023
A small, phase II clinical trial of the oral antihistamine clemastine
previously showed that it modestly improved the transmission of electrical signals in the optic nerve in participants with MS who had optic nerve damage. Now, this team has published new data, based on follow-up studies of this population using novel imaging techniques to examine a major nerve center in the brain called the corpus callosum. This follow-up study, while not a primary outcome of the original study, shows evidence of myelin repair in this nerve center, which was maintained even after treatment stopped.
More studies are needed before the full benefits and risks of this approach can be verified. Several studies are
underway. This and other strategies may help to restore lost function in MS, one of the Pathways to Cures identified in the National MS Society roadmap.
Learn more about this global effort to find cures for all people with MS.
Read more about this study from UCSF
Read the paper in Proceedings of the National Academy of Science